Voxel-Based Dosimetry Predicts Local Tumor Progression Post 90Y Radiation Segmentectomy of Colorectal Liver Metastases

被引:3
作者
Dimopoulos, Platon M. [1 ,2 ]
Sotirchos, Vlasios S. [1 ]
Dunne-Jaffe, Cynthia [1 ,3 ]
Petre, Elena N. [1 ]
Gonen, Mithat [4 ]
Zhao, Ken [1 ]
Kirov, Assen S. [5 ]
Crane, Christopher [6 ]
D'Angelica, Michael [7 ]
Connell, Louise C. [8 ]
Sofocleous, Constantinos T. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Radiol, Intervent Oncol Radiol Serv, IR Suite H118,1275 York Ave, New York, NY 10065 USA
[2] Univ Hosp Patras, Dept Intervent Radiol, Patras, Greece
[3] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA
[4] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY USA
[5] Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY USA
[6] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY USA
[7] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY USA
[8] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
关键词
radiation segmentectomy; yttrium-90; radioembolization; dosimetry; colorectal liver metastases; stereotactic tumor irradiation; RADIOFREQUENCY ABLATION; HEPATIC METASTASES; PLUS CHEMOTHERAPY; SURVIVAL OUTCOMES; RADIOEMBOLIZATION; CANCER; THERAPY; SAFETY; TRIAL; MULTICENTER;
D O I
10.1097/RLU.0000000000005565
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background: Radiation segmentectomy (RS) is an alternative potential local curative treatment for selected colorectal liver metastases (CLMs) not amenable to ablation or limited resection. Purpose: The aim of this study was to evaluate the dosimetric response of low volume CLMs to RS in heavily pretreated patients who are not candidates for resection or percutaneous ablation. Patients and Methods: This single-center retrospective study evaluated CLMs patients treated with RS (prescribed tumor dose >190 Gy) from 2015 to 2023. RS doses to tumor(s) and margins were calculated from SPECT/CT and PET/CT images. Response and local tumor progression (LTP) were assessed using anatomic (RECIST 1.1) and metabolic (PERCIST) criteria. LTP-free survival (LTPFS) and overall survival were estimated with Kaplan-Meier methodology. Variables were assessed as predictors of LTPFS using the Cox proportional hazards model. Results: Thirty-six patients underwent 38 RS procedures to treat 57 tumors. Median time from initial diagnosis to detection of liver metastases and RS were 16.4 (interquartile range: 6.5-32.2) and 26.8 (interquartile range: 12.5-40.0) months, respectively. Median overall survival after RS was 14.3 (95% confidence interval [CI]: 10.8-30.7) months. Predictors of LTPFS included tumor number(s), mean tumor dose (MTD), and margin mean absorbed dose (MMAD). Complete radiographic (hazards ratio [HR]: 1.29e-16, 95% CI: 4.06e-17-4.07e-16, P < 0.001) and metabolic response (HR: 0.38, 95% CI: 0.15-0.95, P = 0.038) correlated with prolonged LTPFS. One-year LTPFS rate was 83.3% for tumors receiving MTD >= 400 Gy and a 5-mm surrounding MMAD >= 350 Gy (P = 0.006). No instances of LTP were observed when tumors received stereotactic irradiation over 300 Gy (at least 95% of the tumor volume received >= 300 Gy). One-year LTPFS rate for tumors receiving MTD >= 400 Gy was 68.6% versus 14.3% for those that did not reach this threshold (P = 0.013). In multivariate analysis, MTD >= 400 Gy and 5-mm MMAD >= 350 Gy were independent predictors of LTPFS (HR: 0.11; 95% CI: 0.01-0.81; P = 0.03). Conclusions: MTD >= 400 Gy, MMAD >= 350 Gy, and stereotactic tumor irradiation >= 300 Gy are associated with prolonged LTPFS after RS for CLMs.
引用
收藏
页码:133 / 142
页数:10
相关论文
共 41 条
[1]   Current Status and Future Direction of Hepatic Radioembolisation [J].
Alsultan, A. A. ;
Braat, A. J. A. T. ;
Smits, M. L. J. ;
Barentsz, M. W. ;
Bastiaannet, R. ;
Bruijnen, R. C. G. ;
de Keizer, B. ;
de Jong, H. W. A. M. ;
Lam, M. G. E. H. ;
Maccauro, M. ;
Chiesa, C. .
CLINICAL ONCOLOGY, 2021, 33 (02) :106-116
[2]   Metastatic Colon Cancer, Version 3.2013 [J].
Benson, Al B., III ;
Bekaii-Saab, Tanios ;
Chan, Emily ;
Chen, Yi-Jen ;
Choti, Michael A. ;
Cooper, Harry S. ;
Engstrom, Paul F. ;
Enzinger, Peter C. ;
Fakih, Marwan G. ;
Fenton, Moon J. ;
Fuchs, Charles S. ;
Grem, Jean L. ;
Hunt, Steven ;
Kamel, Ahmed ;
Leong, Lucille A. ;
Lin, Edward ;
May, Kilian Salerno ;
Mulcahy, Mary F. ;
Murphy, Kate ;
Rohren, Eric ;
Ryan, David P. ;
Saltz, Leonard ;
Sharma, Sunil ;
Shibata, David ;
Skibber, John M. ;
Small, William, Jr. ;
Sofocleous, Constantinos T. ;
Venook, Alan P. ;
Willett, Christopher G. ;
Gregory, Kristina M. ;
Freedman-Cass, Deborah A. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (02) :141-152
[3]   Yttrium-90 Radiation Segmentectomy in Oligometastatic Secondary Hepatic Malignancies [J].
Chiu, Andrew M. ;
Savoor, Rohan ;
Gordon, Andrew C. ;
Riaz, Ahsun ;
Sato, Kent T. ;
Hohlastos, Elias ;
Salem, Riad ;
Lewandowski, Robert J. .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2023, 34 (03) :362-368
[4]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[5]   Yttrium-90 for colorectal liver metastasis-the promising role of radiation segmentectomy as an alternative local cure [J].
Entezari, Pouya ;
Gabr, Ahmed ;
Salem, Riad ;
Lewandowski, Robert J. .
INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2022, 39 (01) :620-626
[6]   Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial [J].
Garlipp, B. ;
Gibbs, P. ;
Van Hazel, G. A. ;
Jeyarajah, R. ;
Martin, R. C. G. ;
Bruns, C. J. ;
Lang, H. ;
Manas, D. M. ;
Ettorre, G. M. ;
Pardo, F. ;
Donckier, V. ;
Benckert, C. ;
van Gulik, T. M. ;
Goere, D. ;
Schoen, M. ;
Pratschke, J. ;
Bechstein, W. O. ;
de la Cuesta, A. M. ;
Adeyemi, S. ;
Ricke, J. ;
Seidensticker, M. .
BRITISH JOURNAL OF SURGERY, 2019, 106 (13) :1837-1846
[7]   Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies [J].
Gibbs, Peter ;
Heinemann, Volker ;
Sharma, Navesh K. ;
Taieb, Julien ;
Ricke, Jens ;
Peeters, Marc ;
Findlay, Michael ;
Robinson, Bridget ;
Jackson, Christopher ;
Strickland, Andrew ;
Gebski, Val ;
Van Buskirk, Mark ;
Zhao, Huaqing ;
van Hazel, Guy .
CLINICAL COLORECTAL CANCER, 2018, 17 (04) :E617-E629
[8]   Recommendations for the management of yttrium-90 radioembolization in the treatment of patients with colorectal cancer liver metastases: a multidisciplinary review [J].
Gonzalez-Flores, Encarna ;
Zambudio, Natalia ;
Pardo-Moreno, Pedro ;
Gonzalez-Astorga, Beatriz ;
de la Rua, Jorge Roldan ;
Trivino-Ibanez, Eva M. ;
Navarro, Pablo ;
Espinoza-Camac, Nataly ;
Casado, Miguel angel ;
Rodriguez-Fernandez, Antonio .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (04) :851-863
[9]   Assessment of Liver Tumor Response to Therapy: Role of Quantitative Imaging [J].
Gonzalez-Guindalini, Fernanda D. ;
Botelho, Marcos P. F. ;
Harmath, Carla B. ;
Sandrasegaran, Kumaresan ;
Miller, Frank H. ;
Salem, Riad ;
Yaghmai, Vahid .
RADIOGRAPHICS, 2013, 33 (06) :1781-1800
[10]   Randomised trial of SIR-Spheres® plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer [J].
Gray, B ;
Van Hazel, G ;
Hope, M ;
Burton, M ;
Moroz, P ;
Anderson, J ;
Gebski, V .
ANNALS OF ONCOLOGY, 2001, 12 (12) :1711-1720